A study that evaluated a PARP inhibitor (niraparib) in males with metastatic prostate cancer found that those with a BRCA1 or BRCA2 mutation lived longer on average than those who did not have a BRCA mutation.
Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35131040/
Reference:
Smith et al. Lancet Oncol. 2022;23(3):362-373. PMID: 35131040.